SEC Comment Letter for PRECISION BIOSCIENCES (DTIL) — Jan 2, 2026
PRECISION BIOSCIENCES INC
Date: Jan. 2, 2026 · CIK: 0001357874 · Accession: 0000000000-26-000019
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292478
Letter
Re: Precision BioSciences, Inc. Registration Statement on Form S-3 Filed December 30, 2025 File No. 333-292478 Dear Michael Amoroso:
January 2, 2026
Michael Amoroso President and Chief Executive Officer Precision BioSciences, Inc. 302 East Pettigrew St., Suite A-100 Durham, North Carolina 27701
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Nathan Ajiashvili, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> January 2, 2026 Michael Amoroso President and Chief Executive Officer Precision BioSciences, Inc. 302 East Pettigrew St., Suite A-100 Durham, North Carolina 27701 Re: Precision BioSciences, Inc. Registration Statement on Form S-3 Filed December 30, 2025 File No. 333-292478 Dear Michael Amoroso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nathan Ajiashvili, Esq. </TEXT> </DOCUMENT>